Advice
following a full submission:
rivaroxaban (Xarelto®) is accepted for use within NHS Scotland.
Indication under review: treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.
Rivaroxaban has been shown to be non-inferior to standard anticoagulant therapy including a low molecular weight heparin in combination with a vitamin K antagonist for the treatment of proximal DVT and prevention of recurrence.
Experience with rivaroxaban in this indication for more than 12 months is limited therefore the cost-effectiveness of indefinite treatment has not been demonstrated.
Download detailed advice162KB (PDF)
Medicine details
- Medicine name:
- rivaroxaban (Xarelto) DVT
- SMC ID:
- 755/12
- Indication:
- For the treatment of DVT and prevention of recurrent DVT & pulmonary embolism following acute DVT in adults
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 February 2012